Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Richard Belanger who wrote (30272)	1/14/2000 12:37:00 PM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

Rich, Count one NO. Do we all get votes proportional to the number of shares we control? :-) Cheers, Torben

To: Richard Belanger who wrote (30272)	1/14/2000 12:39:00 PM
From: Henry Niman	Respond to of 32384

I suspect that many of the long term buyers would be unhappy with $30, including Robinson and other insiders. If they sold at $30, it would be because the Targretin breast cancer data was weak. Company really has too many things going for it to sell out that cheaply. A couple of days ago I was talking to a former PFE salesperson (with SGP now). He had a friend who was among the 40 new hires by LGND and he wanted to get up to speed, so he could psyche out away his friend with his knowledge about LGND's products. I told him about the various alliances that LGND had, including the 4 SERM deals and it just blew him away. As a salesperson, he knew what a big seller SERMs could be for treatment and PREVENTION of breast cancer, osteoporosis, and heart disease (all in one pill) and knew that eventually, such a pill would be a tremendous seller. When he heard that LGND had SERM deals with PFE, AHP, LLY, and WLA he was ready to place his LGND order. Of course LGND has a huge RXR/PPAR program for diabetes, obesity, and cardiology, representing yet another huge market. As long as LGND can get the bucks rolling in from its three approved products, they will be a force to be reckoned with, in the Pharma (not Biotech) arena.